- New appointments bring expertise and proven leadership to
ZyVersa to support advancement and development of VAR 200 for renal
disease, and IC 100 for inflammatory diseases
Fla., Jan. 5, 2023 /PRNewswire/ -- ZyVersa
Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa"), a clinical- stage
specialty biopharmaceutical company developing first-in-class drugs
for treatment of renal and inflammatory diseases with high unmet
medical needs, announced today the appointments of three new
independent board members, bringing the total board membership to
ZyVersa appoints three new independent
board members, bringing the total board membership to seven.
The existing board of ZyVersa appointed the following new board
members: Gregory G. Freitag, J.D.,
CPA; Katrin Rupalla, PhD; and James
Sapirstein. The new board members will join Robert G. Finizio, Executive Director of
PleoPharma; Daniel O'Connor, Chief
Executive Officer, Co-founder, and Director of Ambrx Biopharma;
Minchul Park, PhD, Chief Executive
Officer, and Director of Curebio; and ZyVersa's Chief Commercial
Officer and President, Stephen C.
Glover, who also serves as chairman of the ZyVersa
"We are delighted to welcome our three new board members
at this important time in ZyVersa's evolution," stated Stephen C. Glover. "As biopharmaceutical leaders
with impeccable credentials and a proven track record of success,
their knowledge and perspectives will be invaluable as we progress
development of our company and our lead renal and anti-inflammatory
assets. We look forward to their contributions and
Gregory G. Freitag, J.D.,
Mr. Freitag has more than 30 years of executive management,
legal and financial experience in the Life Science, Medical Device,
and Healthcare markets. Currently, he serves as a board member of
PDS Biotechnology a clinical-stage immunotherapy company developing
a growing pipeline of targeted cancer and infectious disease
immunotherapies, and AxoGen, Inc., a leading regenerative medicine
company dedicated to peripheral nerve repair. Prior to retirement,
Mr. Freitag served as Axogen's General Counsel, Chief Financial
Officer, and Senior Vice President of Business Development. Mr.
Freitag has held executive positions at LecTec Corporation, which
merged with AxoGen in September 2011;
Pfizer Health Solutions, a former subsidiary of Pfizer, Inc.;
Guidant Corporation; HTS Biosystems; and Quantech, Ltd.
Katrin Rupalla, PhD
Dr. Rupalla has more than 25 years of experience in development,
primarily in the areas of oncology, immunology, and neurology.
Currently she is Chief Executive Officer and Founder of Ymmunobio
AG, a preclinical stage oncology biotech company developing two
novel classes of therapeutic antibodies to treat cancer. Dr.
Rupalla is also the Chair of the board of AMBRX, and a board member
of the non-profit Cancer Drug Development Forum. Dr. Rupalla has
held several leadership positions in pharmaceutical companies
including Lundbeck, BMS, Celgene and Roche. Her regulatory and drug
development career includes several world-wide approvals of major
oncology and hematology products, and a multitude of new indication
approvals in various therapeutic areas.
Mr. Sapirstein has served for over thirty-eight years in the
pharmaceutical industry. He is currently the Chairman, Chief
Executive Officer, and President of First Wave BioPharma (NASDAQ:
FWBI), a clinical stage biopharmaceutical company specializing in
the development of targeted, non-systemic therapies for
gastrointestinal diseases. He also holds board positions at
Enochian Biosciences, Blue Water Vaccines, and BIO, the leading
biotechnology trade organization promoting public policy and
networking in the healthcare space, where he sits on the Emerging
Companies Section Governing Board. Mr. Sapirstein has held
executive positions at ContraVir Pharmaceuticals; Alliqua, Inc.;
Tobira Therapeutics, which was acquired by Allergan; Serono
Laboratories; and Gilead Sciences. He has raised over $300 Million dollars in venture capital and
public capital markets financing in his various engagements as
Chief Executive Officer.
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company
leveraging advanced, proprietary technologies to develop
first-in-class drugs. Our focus is on patients with renal or
inflammatory diseases who have significant unmet medical needs. Our
development pipeline includes phase 2a-ready VAR 200, a cholesterol
efflux mediator for treatment of rare kidney disease, focal
segmental glomerulosclerosis (FSGS). VAR 200 has potential to treat
other kidney diseases, such as Alport Syndrome and Diabetic Kidney
Disease. It also includes a novel inflammasome ASC inhibitor with
potential to treat multiple CNS and other inflammatory diseases.
For more information, please visit www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management's intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc ("ZyVersa") uses words such as
"anticipates," "believes," "plans," "expects," "projects,"
"future," "intends," "may," "will," "should," "could," "estimates,"
"predicts," "potential," "continue," "guidance," and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa's expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa's plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa's planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa's preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa's plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa's product candidates; ZyVersa's
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa's ability to protect its intellectual property
position; and ZyVersa's estimates regarding future revenue,
expenses, capital requirements and need for additional
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
View original content to download
SOURCE ZyVersa Therapeutics, Inc.